Eltrombopag Olamine and Filgrastim in Mobilizing Stem Cells in Patients with Multiple Myeloma Undergoing Peripheral Blood Stem Cell Transplant

Inclusion Criteria

• Participants must have a diagnosis of multiple myeloma documented by having > 15% plasma cells on bone marrow biopsy and/or monoclonal protein in blood and/or urine; all patients must have disease which is either stable or responsive after a minimum of 2 cycles of conventional chemotherapy and slated to undergo autologous peripheral blood stem cell transplantation incorporating mobilization chemotherapy for peripheral blood stem cell collection
• All necessary baseline studies for determining eligibility must be obtained within 42 days of registration unless otherwise stated
• Performance status (Eastern Cooperative Oncology Group [ECOG]) =< 2
• Total bilirubin < 1.5 mg/dl
• Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamic pyruvate transaminase [SGPT]) =< 2.5 X institutional upper limit of normal (ULN)
• Creatinine < 3 mg/dl
• Diffusing capacity of carbon monoxide >= 50% of predicted
• Left ventricular ejection fraction measured by multi-gated acquisition scan (MUGA) or echocardiogram (ECHO) >= 45%
• Ability to understand and the willingness to sign a written informed consent document
• Subjects must be willing to adhere to the study visit schedule and other protocol requirements

Exclusion Criteria

• Myocardial infarction within 6 months of treatment
• Participants may not be receiving any other study agents
• Pregnant and lactating women
• Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, psychiatric illness/social situations that would limit compliance with study requirements, or other significant disease of non-myelomatous origin
• Patients with evidence of active thromboembolic disease, recent history of thromboembolic disease within the past 6 months, or risk factors for thromboembolic disease (excluding thrombosis of a central line)
• Previous history of primary platelet disorder or bleeding disorder
• Individuals with a history of a different malignancy are ineligible except for the following circumstances; individuals with a history of other malignancies are eligible if they have been disease free for at least 5 years and are deemed by the investigator to be at low risk for recurrence of that malignancy; individuals with the following cancers are eligible if diagnosed and treated within the past 5 years: cervical cancer in situ, prostate cancer in situ, and basal cell or squamous cell carcinoma of the skin
• Patients of East Asian ancestry